RxDoctor Payments Data

Ian Stein, MD

Neurology · Great Neck, NYNPI 1710932520

Payments from drug & device makers

$10,575in general payments, 2019–2025

Across 288 payments — averaging $36.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Biogen$794
  • Eisai Inc.$628
  • Amgen$498
  • Teva Pharmaceuticals USA, Inc.$471
  • Harmony Biosciences LLC$448
  • plus $4K from 40 others

What the payments were for

  • Speaking & faculty fees$1,92518%
  • Food & beverage$8,40780%
  • Education$2422%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,575 in reported general payments places this provider in the 70th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$670,652
Medicare patients
446
Services billed
30,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5042$496,914
OctagamImmun Globg(Igg)/Malt/Iga Ov5024$424,359
PanzygaImmun Glob G(Igg)-Ifas/Glycine22$409,780
Gamunex-CImmune Globul G/Gly/Iga Avg 4617$218,106
GammakedImmune Globul G/Gly/Iga Avg 4622$129,624
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5017$125,788
UbrelvyUbrogepant58$66,815
Nurtec OdtRimegepant Sulfate33$54,298
Aimovig AutoinjectorErenumab-Aooe62$53,559
AptiomEslicarbazepine Acetate26$30,169
Dihydroergotamine Mesylate13$24,053
NeuproRotigotine27$20,826
VyvanseLisdexamfetamine Dimesylate18$14,581
BriviactBrivaracetam11$14,433
QuliptaAtogepant11$11,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Panzyga, Nurtec Odt$28$888,43779 claims
CSL BehringPrivigen$252$496,91442 claims
Grifols USA, LLCGamunex-C$176$218,10617 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Vyvanse$55$140,36935 claims
AbbVieUbrelvy, Qulipta$3,293$78,21169 claims
UCB, Inc.Neupro, Briviact$250$35,26038 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$155$1,18734 claims
Upsher-smith Laboratories LLCTopiramate$17$55942 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,623 neurology providers in New York.

Other neurology in Great Neck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →